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Perhaps contrary to reader’s expectations, there is no 
divergence in the views of the authors concerning the use-
fulness of genetic testing as a means of determining cancer 
risk. The only differences lie in their views on the potential for 
practical use of recognised cancer markers. We both agree 
that further research is required to seek new markers or sur-
rogate markers. Our perception of the future is hopeful; we 
anticipate that knowledge of cancer will soon attain a level 
that permits more precise diagnoses of disease susceptibility 
and facilitates early detection and an informed choice of the 
optimal therapy for any given molecular subtype of cancer. 
We thus decided to compose this article together, without 
specifically emphasising any of the slight differences in our 
perspectives. 
Genetic variation between any two randomly chosen 
human individuals is never greater than 0.5%. Such ap-
parently small differences are nevertheless responsible for 
variability in susceptibility to disease. If we accept the basic 
premise that the majority of diseases arise from disorders 
at the molecular and genetic levels, resulting from inter-
actions between genetic disposition and environmental 
factors, then almost all diseases can be classified into three 
categories: 1) single-gene disease, 2) polygenic disease, and 
3) complex disease (multifactorial, where environmental ef-
fects predominate). Underlying the first two categories are 
gene alterations that increase morbidity. Such gene changes 
are rare in the population; however, they usually achieve 
high penetrance. These changes may concern: 1) the loss 
or acquisition of chromosome(s); 2) rearrangement and loss 
or acquisition of chromosome fragments (i.e., chromosome 
aberrations); 3) the loss or acquisition of short nucleotide 
sequences; 4) substitution, insertion or deletion of individual 
nucleotides within the DNA sequence; and 5) epigenetic 
changes, not associated with changes in DNA sequence. By 
contrast, multifactorial diseases, arise as a result of multiple 
genetic determinants, mainly consisting of single nucleotide 
polymorphisms (SNPs), which represent more than 90% of 
genetic variation and whose incidence in the population is 
above 1%; this incidence being sufficiently high to make the 
random appearance of a SNP in the population very likely. 
These changes are relatively common in the general popula-
tion and, on account of the discrete selection of particular 
determinants, can increase susceptibility to disease only by 
an accumulating effect. In a consequence, the incidence of 
most disorders is a cumulative result of the “weak” genetic 
alterations with additive effects and a set of environmental 
expositions.
An individual’s phenotype is comprised of the sum of 
the cell-specific, developmental-stage-specific, and metab-
olism-related changes in gene expression, while individual 
susceptibility to disease is based on genetic variance, which 
determines the patient’s defense and adaptive mechanisms 
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against environmental factors, particularly on the molecu - 
lar level. The main sources of variability in the genetic 
material of somatic cells are imperfect DNA replication and 
mutations arising from exposure to physical, chemical, and 
biological mutagenic agents. In turn, the processes involved 
in preventing DNA damage have been shaped by evolution 
and are tightly controlled by mechanisms that prevent ex-
cessive genetic diversity. The cell possesses seven primary 
and approximately fifteen salvage systems for repair of its 
genetic material; thereby, the vast majority of errors in DNA 
sequences are corrected. In cases where repair is ineffective, 
because damage is too severe, cells are effectively eliminat-
ed by a process leading to cell death, termed apoptosis, or 
programmed cell death. Despite the excellent mechanisms 
in place for regulation of the genome, genomic chang-
es are, nevertheless, periodically duplicated and can lead 
to increased morbidity in response to pathogenic stimuli; 
however, such errors are not inherited by offspring, unless 
they occur in reproductive cells.
Cancer is a classic example of a polygenic disease caused 
by simultaneous errors in numerous genes. The damage 
may not necessarily be a mutation (i.e., a change in the DNA 
sequence), but can be any change which causes the product 
of the defective gene to either lose, or change (increase or 
decrease), its ability to fulfil its biological function. Simul-
taneous failures in many cellular processes lead to a loss of 
homeostasis. For a cell to be transformed into a cancer cell 
(i.e., malignant transformation), such changes may occur in 
a few, or even several tens, of genes. These changes must 
involve driver genes, since only changes in these genes are 
capable of eliciting malignant transformation. Changes in 
passenger genes, which can affect tumour phenotype, do 
not by themselves induce carcinogenesis. Although there 
are relatively few driver genes, they are markedly variable 
dependent on cancer type; hence, driver genes in one type 
of tumour may be passenger genes in another malignancy 
and vice versa. In addition, the ability of the same driver 
genes to induce different types of cancer can vary signifi-
cantly; for example, mutations in BRCA1 are more effective 
in inducing transformations leading to breast, than ovar-
ian or prostate, cancers. Although we cannot choose the 
genomic inheritance we receive from our parents, including 
all the variants which determine our body’s susceptibility 
and morbidity in response to disease, we can at least identify 
those genetic changes which make malignant transforma-
tions more likely.
Epidemiological studies demonstrate that, according 
to their type, 5–15% of cancers are familial. The search for 
the reasons why certain cancer types are often found in 
particular families has led to the identification of a group 
of genes, known as ‘susceptibility genes’, for specific dis-
eases. Damage to susceptibility genes increases the risk of 
developing particular types of cancer. Depending on how 
much they increase the chances of disease, genes are referred 
to as having high, medium, and low penetrance. Damaged 
genes with high penetrance may increase the probability of 
developing a disease to a level approaching unity. This group 
includes the genes, BRCA1, BRCA2, PTEN, CDKN2A (p16), TP53, 
and VHL, the effects of damage to which on cellular transfor-
mation was discovered in the previous century. Genes with 
medium penetrance increase the chances of disease several 
fold and include CHEK2, NBS, and PALB2, which, although 
they belong to the driver gene category, have a somewhat 
secondary importance in the process of transformation. By 
contrast, low genetic penetrance is often due to polymorphic 
variants in detoxification genes, such as GST or NLR. 
The majority of cancer predisposition genes exhibit 
tumour suppressor functions and their mutation leads to 
the generation of products that alter a broad range of es-
sential cell processes, such as DNA repair, cell cycle regu-
lation, apoptosis, or differentiation. Some of these genes 
are associated with organ-specific processes; for example, 
mutations in the SLC25A13, ABCB11, FAP, HMBS, and UROD 
genes are associated with hepatocyte metabolism which, 
via the processes leading to liver cirrhosis, increase the 
risk of developing hepatocellular carcinoma. Only a few 
genes increase the risk of developing cancer as a result of 
activating mutations. This group of genes chiefly affect cell 
signalling, either directly or indirectly.
The development of sporadic tumours (i.e., the vast 
majority) most often results from ‘unfavourable coincidence’ 
and is a slow process. The pre-initiation stage, or exposure to 
carcinogens, continues throughout a person’s life, whereas 
the initiation period is between 15 and 30 years, the pro-
motion stage a few years, and progression takes place over 
several months to several years. Furthermore, tumours can 
consist of several-dozen clones of tumour cells, with differ-
ing changes in their genomes. This results in different clini-
cal disease courses and a variable response to treatment, 
because those types of cancer that are homogeneous from 
a clinical viewpoint can vary greatly at the molecular level. 
For this reason, identification of molecular changes may 
facilitate practical decisions on the type and optimisation 
of treatment and, in some cases, can even prevent disease.
Regrettably, the biology of cancer is still only partially 
understood, and the linking of numerous phenomena into 
a logical sequence of events is frequently based on wishful 
thinking. In the vast majority of cases, decisions on cancer 
treatment are based on relatively limited knowledge about 
the biological processes that have been altered during tu-
mour proliferation. In addition, tumours are treated, to some 
extent, as homogenous entities. This approach is a major 
reason underlying the failure of the clinical implementation 
of biomarkers. We should, therefore, not be asking whether 
new genetic tests to determine cancer risk can be useful, 
but rather why does modern medicine use such a limited 
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number of genetic tests that could otherwise enable the 
most precise diagnoses to be made, followed by choice of 
the most advantageous therapy. 
Rates of breast cancer in Poland stand at 12%, while the 
frequency of somatic BRCA1 gene mutations in breast cancer 
does not exceed 3%. Germline BRCA1 mutation increases 
the morbidity risk by up to approximately 80% throughout 
the life of a woman, and there is a lower lifetime risk for 
a woman inheriting a BRCA2 mutation of around 45%. In 
addition to pathogenic mutations in the BRCA1 and BRCA2 
genes, mutations in the medium penetrance PALB2 and 
CHEK2 genes play an important role in familial breast can-
cer. Hence, although it may seem as though the majority 
of driver genes for breast cancer development are known, 
our present state of knowledge only allows us to explain 
approximately 30% of cases of this type of cancer with 
a strong genetic contribution, indicating that the absence of 
mutations in genes known to predispose to disease does not 
prevent disease morbidity/susceptibility, rather it reduces 
the likelihood of its occurrence.
Disease diagnosis and classification depend on phe-
notype imaging. Modern medicine primarily uses anatom-
ic imaging at both macroscopic and microscopic levels, 
thereby facilitating diagnosis when disease symptoms are 
initially exhibited, or by chance findings of abnormalities. 
Only screening can allow a disease to be intentionally de-
tected early in its asymptomatic period; however, screening 
whole populations is an expensive business and difficult to 
organise. Increasing the effectiveness of screening, while 
substantially reducing health care costs, would be possible 
through medical surveillance of subpopulations of healthy 
people for whom molecular genetic testing indicates an 
increased risk of cancer development. Research already 
permits molecular diagnosis of many single-gene diseases 
and is also available (unfortunately rarely) for some cases of 
polygenic disease. In those cancer cases where the ‘predis-
position genes’ are known, genetic testing allows disease 
risk to be assessed. However, only by the introduction of 
medical research procedures employing highly efficient 
technologies, in particular the so-called ‘Next Generation 
Sequencing’ (NGS), can there be a chance of creating new 
and more efficient health care, both at the level of individual 
patients and that of the whole population.
Genetic association studies constitute the fundamental 
method of searching for new pathogenic variants. Selecting 
the appropriate method for an association study depends 
on the force of impact and incidence of the pathogenic 
genetic variant under study. When seeking high-impact 
individual genetic variants, that translate into a high risk of 
disease development, genetic testing may involve individu-
als, or families, and the basic study method is large-scale 
sequencing of either the entire genome, or only the coding 
sequences of all genes (i.e., exomes), which harbour more 
than 85% of pathogenic mutations in ‘cancer genes’. When 
numerous SNPs of low impact are sought, microarray tech-
nology, which allows Genome-Wide Association Studies 
(GWAS) to be performed, is chiefly used. Modern microar-
rays can analyse several million polymorphisms in a single 
measurement. Since, at the level of polymorphisms, the 
magnitudes of associations are generally less than 1.5, only 
the use of single study populations consisting of several to 
tens of thousands of patients and healthy controls will per-
mit a statistically significant association to be demonstrated.
Another problem requiring rapid solution is that of the 
ability to differentiate between a pathogenic variant associ-
ated with predisposition to disease morbidity/susceptibility 
(mutations in driver genes) and variants in accompanying 
genes that have no effect on cancer development. Genomic 
DNA constitutes a huge assembly of static genetic informa-
tion, variants in which may, but do not necessarily, modify 
the phenotype of the organism; this feature of ‘genetic noise’ 
makes it difficult to identify genuine genotype-phenotype 
associations.
Simple DNA sequencing is insufficient to explain and 
map phenotypic disease changes. Moreover, it is not possi-
ble to determine epigenetic-environment associations, and 
there is no known method to correctly predict pathogenicity 
of genetic variants. Determination of the complete picture 
of the genetic determinants of disease, including cancer, 
would require a catalogue of all relevant variants. In the 
case of oncology, it thus becomes imperative to catalogue 
all ‘cancer genes’, which requires sequencing of thousands 
of genomic DNA samples from tumour cells. This has now 
become technologically possible. Nevertheless, to ensure 
genetic and molecular surveillance for increased disease 
risk, other factors need to be identified, including environ-
mental effects that positively influence health, gene–gene 
and gene–environment interactions, and inherited epige-
netic modifications. This is certainly a difficult task, both in 
terms of the accessibility of research methodologies and 
research organisation.
The importance of ‘empirical treatment’, based on a phy- 
sician’s personal experience, cannot be underestimated 
but should be supported by treatment using information 
derived from the molecular taxonomy of disease. Person-
alisation of cancer treatment should involve adaptation/ 
/tailoring of therapies based on the molecular subtype of 
the tumour. Moreover, inter-individual variability in drug 
metabolism (pharmacogenomics) should also be taken into 
account. Nonetheless, even the implementation of such ob-
vious procedures can lead to difficulties arising from a lack of 
fixed algorithms, qualified personnel, funding mechanisms, 
or regulations; moreover, often there is no evidence for the 
clinical utility of new biomarkers. 
Genetic and molecular descriptions of disease pheno-
types require that physicians and biologists collaborate, 
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both groups providing/delivering clinical and experimental 
data, along with their expertise in the fields they represent, 
and taking advantage of the tools of computational bio-
logy. Such collaborations should lay the foundations for 
integration of genomics into clinical oncology. It is only 
when difficulties in methodical interpretation are over-
come in the performance of molecular and genome wide 
analysis, that medical progress can be clearly accelerated. 
However, until such time as physicians see direct benefits 
of molecular genetic studies for clinical practice, they will 
remain as mere molecular research studies, without any 
practical verification, with only biologists and biotechnolo-
gists involved and no active participation of physicians. For 
this reason, teaching of genetics and molecular biology 
should be introduced into a much wider range of medical 
undergraduate and postgraduate education. Without such 
knowledge physicians are helpless when confronted with 
test results obtained by modern techniques of nucleic acid 
sequencing. In this way, it will also be possible to extend the 
collaboration of the medical fraternity with the developing 
field of molecular medicine.
A genetic counselling network has been established 
in Poland. The majority of centres offer genetic testing, 
where usually one or several cancer predisposition genes 
are assessed; however, only very few provide comprehensive 
information on morbidity/susceptibility risks that include 
oncology surveillance of carriers of mutated genes and their 
families. Genetic testing should be preceded by an analysis 
of the family pedigree by a clinical geneticist, which will al-
low patients to be assigned to specific risk groups, thereby 
guiding the choice of possible genetic testing. Unfortu-
nately, the majority of genetic counselling services (which 
usually having a profit-making ethos) undertake genetic 
testing without those involved having a prior consulta-
tion with a clinical geneticist. In these cases, the outcomes 
obtained are so vague and broad that they do not meet 
the expectations of those tested. Advice given by genetic 
counsellors should be informative, but not provided as com-
mands or in a dictatorial manner. In addition to providing 
direct information about genetic burden, the advice should 
include the following information: 1) whether it is possible 
to, and if so, how to, prevent the onset of disease; 2) how 
to detect the disease at an early stage of development; and 
3) how to limit the consequences of disease. The patient 
should also be advised about informing other members 
of their family of their risk of developing the disease and 
control measures to prevent this from occurring. Under no 
circumstances should test results be used for any purposes 
other than health. The patient and their family should be 
provided with psycho-oncology counselling. Regrettably, 
these legitimate demands are rarely fully met, primarily 
because of a shortage of clinical geneticists and psycho-
oncology counsellors in the Polish health care system. There 
are private companies in the Polish medical market that offer 
a plethora of genetic testing, usually only for the so-called 
‘cancer genes’.
Although genetic counselling (while imperfect) is 
a positive contributing factor in developing a surveillance 
programme for those vulnerable to developing familial 
cancers, actual establishment of genetic surveillance for 
rare cancers remains an unsolved problem. There are no 
rules nor procedures regarding studies that evaluate the 
effect of environmental factors on the human body over 
a lifetime; therefore, the early diagnosis of selected types of 
cancer (such as breast, colorectal, cervix, or prostate cancer) 
still represents the key function of screening programs.
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